Volume 32, Issue 217 (1-2023)
J Mazandaran Univ Med Sci 2023, 32(217): 105-112 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rameshgar M, Bahar A, Eslami Jouibari M, Hedayatizadeh-Omran A, Shojaei-Asrami R, Alizadeh-Navaei R. Association of Diabetes and Metformin Use with
Gastric Cancer: A Case-Control Study. J Mazandaran Univ Med Sci 2023; 32 (217) :105-112
URL: http://jmums.mazums.ac.ir/article-1-15785-en.html
URL: http://jmums.mazums.ac.ir/article-1-15785-en.html
Mahtab Rameshgar 
, Adeleh Bahar , Mohammad Eslami Jouibari , Akbar Hedayatizadeh-Omran , Reyhaneh Shojaei-Asrami , Reza Alizadeh-Navaei
, Adeleh Bahar , Mohammad Eslami Jouibari , Akbar Hedayatizadeh-Omran , Reyhaneh Shojaei-Asrami , Reza Alizadeh-Navaei
Abstract: (1221 Views)
Background and purpose: Recently, several studies have shown type 2 diabetes to be associated with gastric cancer and metformin appears to inhibit the growth of cancer cells by inducing apoptosis. This study was conducted to investigate the relationship between metformin and gastric cancer.
Materials and methods: This case-control study included patients with gastric cancer (case group, n= 121) and a family member of patients with cancer (control group, n= 119). Diabetes history, duration and management of glucose level were recorded in a checklist and data were analyzed in SPSS applying T-test and Chi-square test. Also, logistic regression was used to calculate the odds ratio.
Results: There were significant differences between the case group and control group in terms of age, gender, place of residence, level of education, BMI, and smoking (P<0.05). The adjusted odds ratio for history of diabetes was 0.87 (Adjusted OR=0.87, CI95%: 0.3-2.35) which was not significant (P=0.751). The study showed no significant difference between the two groups in history of diabetes control drugs (including metformin) (P>0.05).
Conclusion: According to current study, it appears that, in north of Iran, there is no association between gastric cancer and diabetes, control drugs (including metformin), and other factors such as duration of diabetes or a family history of diabetes.
Materials and methods: This case-control study included patients with gastric cancer (case group, n= 121) and a family member of patients with cancer (control group, n= 119). Diabetes history, duration and management of glucose level were recorded in a checklist and data were analyzed in SPSS applying T-test and Chi-square test. Also, logistic regression was used to calculate the odds ratio.
Results: There were significant differences between the case group and control group in terms of age, gender, place of residence, level of education, BMI, and smoking (P<0.05). The adjusted odds ratio for history of diabetes was 0.87 (Adjusted OR=0.87, CI95%: 0.3-2.35) which was not significant (P=0.751). The study showed no significant difference between the two groups in history of diabetes control drugs (including metformin) (P>0.05).
Conclusion: According to current study, it appears that, in north of Iran, there is no association between gastric cancer and diabetes, control drugs (including metformin), and other factors such as duration of diabetes or a family history of diabetes.
Type of Study: Research(Original) |
Subject:
Epidemiology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
